The study is designed to look at the usefulness and safety of SUVN-G3031 or placebo for the treatment of excessive daytime sleepiness. Study staff nor the participants will know if they are receiving a study drug or placebo. Participants will be male or female subjects 18-50 years old with a diagnosis of narcolepsy. The study will last approximately 3 to 7 weeks with 5 visits for an individual subject. Study drug will be administered as a pill.

The study is designed to look at the usefulness and safety of AXS-12 or placebo for the treatment of Narcolepsy. The open-label treatment period is 24 weeks, which will be followed by a double-blind treatment period of 4 weeks, for a total of up to 28 weeks with 13 visits. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. Study staff nor the participants will know if they are receiving a study drug or placebo. Participants will be male or female subjects 15-75 years old with a diagnosis of narcolepsy. Study drug will be administered as a pill.

The study is designed to look at the usefulness and safety of switching patients from Xyrem to XYWAV in the treatment of narcolepsy. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. Participants will be male or female subjects 18 to 80 years old. An estimated total of 100 participants are expected to be enrolled in this study. The study treatment period from screening to follow-up will last approximately 17 weeks.

The study is designed to look at the usefulness and safety of AXS-12 or placebo for the treatment of Narcolepsy. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. Study staff nor the participants will know if they are receiving a study drug or placebo. Participants will be male or female subjects 15-75 years old with a diagnosis of narcolepsy. The study will last approximately 28 weeks with 8 visits for an individual subject. Study drug will be administered as a pill.

The purpose of this study is to evaluate the safety and effectiveness of suvorexant versus placebo (an inactive substance) on individuals with alcohol use disorder experiencing insomnia during abstinence. Participants will be 18 years of age or older. Twenty-four participants will have a 50:50 chance to the study drug or placebo. The study participation will last approximately six weeks, requiring four visits.